Delving into the Latest Updates on TR Therapeutics, Inc. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

TLR2(Toll样受体2)	1

关联

1

项与 TR Therapeutics, Inc. 相关的药物

TR-987

靶点

TLR2

作用机制

TLR2调节剂 [+1]

在研机构

TR Therapeutics, Inc. [+1]

原研机构

Kazia Therapeutics Ltd.

在研适应症

慢性静脉功能不全 [+2]

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

5

项与 TR Therapeutics, Inc. 相关的临床试验

NCT06707090

/ Recruiting临床3期

A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

开始日期2024-11-01

申办/合作机构

TR Therapeutics, Inc.

NCT06707103

/ Recruiting临床3期

A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

开始日期2024-11-01

申办/合作机构

TR Therapeutics, Inc.

NCT03154619

/ Active, not recruiting临床2期

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

开始日期2016-11-01

申办/合作机构